GelStat updates SEC filings, positions for future growth
PALM CITY, Fla. — GelStat is primed to grow its OTC remedy business, according to a letter to shareholders and prospective investors released Tuesday.
The company recently updated historic annual and quarterly reports with the Securities and Exchange Commission, noted Gerald Kieft, Gelstat CEO. "GelStat is now positioned to file a form 10 and become a fully reporting company or file the required documents to become an alternative reporting company on the OTC Markets," he wrote. "Either decision will provide better transparency to the investment community."
Kieft shared with investors that GelStat plans to promote its GelStat Migraine and GelStat Sleep products in the direct-to-consumer channel. In addition, GelStat is on the lookout for acquisitions or the distribution rights to additional healthcare products.
"We have already made significant progress on a number of the aforementioned objectives and expect to be releasing additional information soon," Kieft concluded.
Study: Aspirin may block tumor growth in certain patients with colorectal cancer
BIRMINGHAM, Ala. — Aspirin has the potential to block tumor growth in certain patients with colorectal cancer, according to an editorial in the Oct. 25, 2012 issue of the New England Journal of Medicine by a University of Alabama at Birmingham oncologist. In a study that appears in the same issue, researchers examined the use of aspirin in the treatment outcomes of patients with colorectal cancer.
Researchers collected experimental data from 964 patients with colorectal cancer, separating them into two groups based on the presence or absence of a mutation within the PIK3CA gene. The authors found that the use of aspirin after diagnosis in patients with the gene mutation was associated with a 46% reduction in overall mortality and an 82% reduction in colorectal cancer-specific mortality. In contrast, aspirin use in patients without the mutation did not affect either overall or colorectal-specific mortality.
“Approximately 17% of patients with colorectal cancer have a tumor that carries a mutated PIK3CA gene,” stated Boris Pasche, director of the UAB Division of Hematology and Oncology. “Hence, more than one in every six patients with locally advanced colorectal cancer may benefit from this therapy," he wrote. “We haven’t reached the point where we can make a big leap and advise patients to take aspirin to prevent cancer recurrence after surgery, but we are accumulating more information that helps us understand the role that aspirin can potentially play in cancer.”
Leosons Overseas acquires N’Ice, Fiberall brands from Insight Pharmaceuticals
ALBANY — Leosons Overseas on Tuesday announced the acquisition of the brands N’Ice and Fiberall from Insight Pharmaceuticals. Terms of the transaction were not disclosed.
"We are proud of our growth and success of these brands, and we feel that this acquisition will further our mission to deliver the best U.S.-made products globally," said John Ohanian, general manager and president of Leosons. "The acquisition … will broaden our existing sales and distribution reach, as well as bring scale to our business.”
N’Ice lozenges serve as an oral anesthetic and cough suppressant, while Fiberall is a psyllium husk-based, bulk-forming laxative and fiber supplement.